Cargando…
Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome
Pulmonary fibrosis (PF) is a chronic lung disorder characterized by the presence of scarred and thickened lung tissues. Although the Food and Drug Administration approved two antifibrotic drugs, pirfenidone, and nintedanib, that are currently utilized for treating idiopathic PF (IPF), the clinical t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341703/ https://www.ncbi.nlm.nih.gov/pubmed/37446052 http://dx.doi.org/10.3390/ijms241310876 |
_version_ | 1785072325010391040 |
---|---|
author | Tseng, Yu-Hsin Chen, I-Chen Li, Wan-Chun Hsu, Jong-Hau |
author_facet | Tseng, Yu-Hsin Chen, I-Chen Li, Wan-Chun Hsu, Jong-Hau |
author_sort | Tseng, Yu-Hsin |
collection | PubMed |
description | Pulmonary fibrosis (PF) is a chronic lung disorder characterized by the presence of scarred and thickened lung tissues. Although the Food and Drug Administration approved two antifibrotic drugs, pirfenidone, and nintedanib, that are currently utilized for treating idiopathic PF (IPF), the clinical therapeutic efficacy remains unsatisfactory. It is crucial to develop new drugs or treatment schemes that combine pirfenidone or nintedanib to achieve more effective outcomes for PF patients. Understanding the complex mechanisms underlying PF could potentially facilitate drug discovery. Previous studies have found that the activation of inflammasomes, including nucleotide-binding and oligomerization domain (NOD)-like receptor protein (NLRP)1, NLRP3, NOD-like receptor C4, and absent in melanoma (AIM)2, contributes to lung inflammation and fibrosis. This article aims to summarize the cellular and molecular regulatory cues that contribute to PF with a particular emphasis on the role of AIM2 inflammasome in mediating pathophysiologic events during PF development. The insights gained from this research may pave the way for the development of more effective strategies for the prevention and treatment of PF. |
format | Online Article Text |
id | pubmed-10341703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103417032023-07-14 Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome Tseng, Yu-Hsin Chen, I-Chen Li, Wan-Chun Hsu, Jong-Hau Int J Mol Sci Review Pulmonary fibrosis (PF) is a chronic lung disorder characterized by the presence of scarred and thickened lung tissues. Although the Food and Drug Administration approved two antifibrotic drugs, pirfenidone, and nintedanib, that are currently utilized for treating idiopathic PF (IPF), the clinical therapeutic efficacy remains unsatisfactory. It is crucial to develop new drugs or treatment schemes that combine pirfenidone or nintedanib to achieve more effective outcomes for PF patients. Understanding the complex mechanisms underlying PF could potentially facilitate drug discovery. Previous studies have found that the activation of inflammasomes, including nucleotide-binding and oligomerization domain (NOD)-like receptor protein (NLRP)1, NLRP3, NOD-like receptor C4, and absent in melanoma (AIM)2, contributes to lung inflammation and fibrosis. This article aims to summarize the cellular and molecular regulatory cues that contribute to PF with a particular emphasis on the role of AIM2 inflammasome in mediating pathophysiologic events during PF development. The insights gained from this research may pave the way for the development of more effective strategies for the prevention and treatment of PF. MDPI 2023-06-29 /pmc/articles/PMC10341703/ /pubmed/37446052 http://dx.doi.org/10.3390/ijms241310876 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tseng, Yu-Hsin Chen, I-Chen Li, Wan-Chun Hsu, Jong-Hau Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome |
title | Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome |
title_full | Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome |
title_fullStr | Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome |
title_full_unstemmed | Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome |
title_short | Regulatory Cues in Pulmonary Fibrosis—With Emphasis on the AIM2 Inflammasome |
title_sort | regulatory cues in pulmonary fibrosis—with emphasis on the aim2 inflammasome |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341703/ https://www.ncbi.nlm.nih.gov/pubmed/37446052 http://dx.doi.org/10.3390/ijms241310876 |
work_keys_str_mv | AT tsengyuhsin regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome AT chenichen regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome AT liwanchun regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome AT hsujonghau regulatorycuesinpulmonaryfibrosiswithemphasisontheaim2inflammasome |